Featured milestones
FDA Fast Track Designation for AV-001
Read morePhase 2a: positive IDSMB recommendation
Read moreExpanded development into severe burns
Read more- May 30, 2024Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001Regulatory Milestones
- Apr 24, 2024American Thoracic Society Selects Vasomune to Present the AV-001 Development Update at the 2024 Respiratory Innovation SummitScientific Presentations
- Nov 14, 2023AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyClinical Progress
- Jan 18, 2022Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001Clinical Progress
- TBCDevelopment of AV-001 expands into severe burn resuscitationPartnership & Development
- TBCVasomune and AnGes expand co-development of AV-001Partnership & Development
- No posts in this category yet.